Document is current
Any future updates will be listed below
-
Authors
Llovet, Josep M. https://orcid.org/0000-0003-0547-2667
Willoughby, Catherine E. https://orcid.org/0000-0002-0617-8833
Singal, Amit G.
Greten, Tim F. https://orcid.org/0000-0002-0806-2535
Heikenwälder, Mathias
El-Serag, Hashem B. https://orcid.org/0000-0001-5964-7579
Finn, Richard S.
Friedman, Scott L. https://orcid.org/0000-0003-1178-6195
- License Information
-
More Information
Article History
Accepted: 3 February 2023
First Online: 17 March 2023
Competing interests
: J.M.L. received research support from Bayer HealthCare Pharmaceuticals, Eisai Inc., Bristol Myers Squibb, Boehringer-Ingelheim and Ipsen and consulting fees from Merck, Eli Lilly, Eisai Inc., Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Exelixis, Ipsen, Genentech, Roche, Glycotest, Nucleix, Mina Alpha Ltd. and AstraZeneca. A.G.S. has served as a consultant or on advisory boards for Bayer, Eisai, Genentech, BMS, Exelixis, AstraZeneca, Wako Diagnostics, Exact Sciences, Roche, Glycotest, GRAIL and TARGET PharmaSolutions. H.B.E.-S. received research support from Glycotest, Gilead Sciences, Merck Sharp & Dohme BV and AbbVie. R.S.F. reports consulting fees from AstraZeneca, Bayer, CStone, BMS, Eisai, Exilixis, Eli Lilly, Pfizer, Merck, Roche/Genentech and Hengrui. S.L.F. is a consultant to 89 Bio, Amgen, Axcella Health, Blade Therapeutics, Bristol Myers Squibb, Can-Fite Biopharma, Casma Therapeutics, ChemomAb, Escient Pharmaceuticals, Forbion, Galmed, Gordian Biotechnology, Glycotest, Glympse Bio, Insitro, Morphic Therapeutics, North Sea Therapeutics, Novartis, Ono Pharmaceuticals, Pfizer Pharmaceuticals, Scholar Rock and Surrozen and has stock options (all less than 1% of company value) in Blade Therapeutics, Escient, Galectin, Galmed, Genfit, Glympse, Hepgene, Lifemax, Metacrine, Morphic Therapeutics, Nimbus, North Sea Therapeutics, Scholar Rock and Surrozen. All other authors declare no competing interests.
